Skip to main content

Table 3 Results of virological and genotypic resistance testing by cohort, Arua, Uganda, 2006

From: Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda

  M12 cohort
(N = 59)
M24 cohort
(N = 27)
HIV RNA < 400 copies/mL (%; 95% CI) 35 (59.3; 46.1-71.3) 9 (33.3; 17.5-54.0)
HIV RNA 400-999 copies/mL (%; 95% CI) 7 (11.9; 5.6-23.3) 1 (3.7; 0.5-24.5)
HIV RNA ≥ 1,000 copies/mL (%; 95% CI) 17 (28.8; 18.5-42.0) 17 (62.9; 42.5-79.7)
   Available genotypic resistance (%) 17 (100) 17 (100)
   Wild type virus (%) 3 (17.6) 1 (5.9)
   Resistance to ≥ 1 ARV drug (%) 13 (76.5) 16 (94.1)
   Resistance to EFV and NVP (%) 0 (0) 0 (0)
   Resistance to 3TC, EFV and NVP (%) 12 (70.6) 6 (35.3)
   Extensive resistancea (%) 0 (0) 8 (47.1)
  1. Note: ARV, antiretroviral; 95% CI, binomial 95% confidence interval; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine.
  2. aResistance to EFV, NVP, 3TC, stavudine, zidovudine or tenofovir and didanosine.